Recap - Questcor Pharmaceuticals imploded. We said shares would rebound after tuning into the company’s conference call and coming out thinking Questcor’s lead product, H.P. Acthar Gel, … Continue Reading
Read nowLong Ideas - A presentation from Idenix Pharmaceuticals (NASDAQ:IDIX) at the UBS Global Life Sciences conference Thursday did little to settle the nerves of IDIX investors who have … Continue Reading
Read nowLong Ideas - In a press release after the markets closed on Thursday, Achillion Pharmaceuticals (NASDAQ:ACHN) announced that the company will be selling $41.8M in common stock to … Continue Reading
Read now- After receiving word from the FDA that lead hepatitis C (HCV) treatment candidate, IDX-184, was placed on partial clinical hold as of mid-August, Idenix Pharmaceuticals … Continue Reading
Read nowQuick Picks - Bristol-Myer’s Squibb (NYSE:BMY) announced last night that it would be officially discontinuing development of its Hepatitis C treatment, known as BMS-986094, and revealed the financial … Continue Reading
Read nowLong Ideas - Idenix Pharmaceuticals (NASDAQ:IDIX) announced today that the FDA has placed its lead compound for hepatitis C, IDX-184, on partial clinical hold. According to IDIX, the … Continue Reading
Read nowQuick Picks - With Gilead (NASDAQ:GILD) paying $11 billion for Pharmasset last year, the action around the next generation of hepatitis C treatments has centered on nucleoside type … Continue Reading
Read now